Update Regarding Forward Guidance
Company clarifies forward revenue guidance does not include Tempus AI collaboration implications.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 24 September 2025 - Renalytix plc (LSE: RENX) a precision medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, provides a further comment regarding revenue guidance following the Company's announcement dated 23 September 2025.
The Company would like to clarify that the forward revenue guidance provided does not include full consideration of the implications of its recently announced collaboration with Tempus AI, Inc. ("Tempus"). As it is too early to predict revenue contributions from this new relationship with Tempus, the Company expects to provide shareholders with updates in due course.
James McCullogh, Chief Executive Officer.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.